跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
TGA
/
RETEVMO selpercatinib 40 mg immediate release capsules
Approved
STANDARD
RETEVMO selpercatinib 40 mg immediate release capsules
Eli Lilly Australia Pty Ltd
🇦🇺 Therapeutic Goods Administration
Approval Date
May 30, 2025
Approval ID
2d188b08c6216ef5
Company
Eli Lilly Australia Pty Ltd
Type
Standard
Approval Details
Approval Id
2d188b08c6216ef5
Product Name
RETEVMO selpercatinib 40 mg immediate release capsules
Artg Id
391331
Artg Name
RETEVMO selpercatinib 40 mg immediate release capsules
Sponsor
Eli Lilly Australia Pty Ltd
Company Detail Path
/organization/eli-lilly-australia-pty-ltd
Artg Date
2023-07-03
Registration Type
Medicine
Therapeutic Good Type
Medicine
Licence Status
A
Licence Category
REP
Consumer Medicine Info
https://medical-cdn.nocode.com/drug_tga/be6f06d5e0c4d602a59ed0dd7476422c.pdf
Product Information
https://medical-cdn.nocode.com/drug_tga/b7e7123b692634c4b3971468717cef37.pdf
Active Ingredients
Approved
Quick Info
Agency
TGA
Country
🇦🇺
Approval Date
May 30, 2025
Approval ID
2d188b08c6216ef5
Type
Standard
Back to TGA Approvals
RETEVMO selpercatinib 40 mg immediate release capsules - TGA Drug Approval Details
